Great Lakes Advisors’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $459K | Hold |
2,026
| – | – | ﹤0.01% | 626 |
|
|
2026
Q1 | $349K | Sell |
2,026
-38
| -2% | -$7.05K | ﹤0.01% | 664 |
|
|
2025
Q4 | $412K | Buy |
+2,064
| New | +$374K | ﹤0.01% | 650 |
|
|
2025
Q1 | – | Sell |
-1,897
| Closed | -$350K | – | 810 |
|
|
2024
Q4 | $350K | Sell |
1,897
-32
| -2% | -$6.16K | ﹤0.01% | 700 |
|
|
2024
Q3 | $380K | Sell |
1,929
-2,347
| -55% | -$488K | ﹤0.01% | 695 |
|
|
2024
Q2 | $883K | Sell |
4,276
-70
| -2% | -$15.9K | 0.01% | 591 |
|
|
2024
Q1 | $1.18M | Sell |
4,346
-349
| -7% | -$83.3K | 0.01% | 531 |
|
|
2023
Q4 | $1.11M | Sell |
4,695
-1,222
| -21% | -$240K | 0.01% | 517 |
|
|
2023
Q3 | $1.16M | Buy |
5,917
+3,688
| +165% | +$757K | 0.01% | 513 |
|
|
2023
Q2 | $469K | Sell |
2,229
-21,128
| -90% | -$4.2M | ﹤0.01% | 607 |
|
|
2023
Q1 | $4.71M | Buy |
23,357
+21,376
| +1,079% | +$4.84M | 0.04% | 379 |
|
|
2022
Q4 | $432K | Sell |
1,981
-146
| -7% | -$31.9K | 0.02% | 519 |
|
|
2022
Q3 | $419K | Sell |
2,127
-58,789
| -97% | -$12.7M | 0.01% | 509 |
|
|
2022
Q2 | $13M | Sell |
60,916
-3,980
| -6% | -$973K | 0.26% | 104 |
|
|
2022
Q1 | $18.4M | Sell |
64,896
-20,005
| -24% | -$6.17M | 0.3% | 93 |
|
|
2021
Q4 | $32M | Sell |
84,901
-2,144
| -2% | -$833K | 0.49% | 59 |
|
|
2021
Q3 | $35.9M | Sell |
87,045
-2,076
| -2% | -$862K | 0.56% | 43 |
|
|
2021
Q2 | $33M | Sell |
89,121
-2,060
| -2% | -$688K | 0.5% | 44 |
|
|
2021
Q1 | $26.4M | Buy |
91,181
+4,056
| +5% | +$1.13M | 0.43% | 57 |
|
|
2020
Q4 | $21.8M | Sell |
87,125
-45,586
| -34% | -$10.9M | 0.39% | 79 |
|
|
2020
Q3 | $30.1M | Buy |
132,711
+23,886
| +22% | +$4.96M | 0.64% | 37 |
|
|
2020
Q2 | $19M | Buy |
108,825
+5,896
| +6% | +$941K | 0.46% | 63 |
|
|
2020
Q1 | $13M | Buy |
102,929
+2,436
| +2% | +$365K | 0.38% | 74 |
|
|
2019
Q4 | $15.4M | Buy |
100,493
+503
| +0.5% | +$69.6K | 0.33% | 73 |
|
|
2019
Q3 | $13.2M | Buy |
99,990
+3,071
| +3% | +$412K | 0.29% | 84 |
|
|
2019
Q2 | $13.8M | Buy |
96,919
+4,358
| +5% | +$591K | 0.3% | 77 |
|
|
2019
Q1 | $13.4M | Sell |
92,561
-14,037
| -13% | -$1.84M | 0.3% | 81 |
|
|
2018
Q4 | $12.1M | Buy |
106,598
+17,394
| +19% | +$2.18M | 0.29% | 89 |
|
|
2018
Q3 | $12M | Sell |
89,204
-5,413
| -6% | -$668K | 0.26% | 81 |
|
|
2018
Q2 | $10.6M | Buy |
94,617
+604
| +0.6% | +$65.3K | 0.25% | 96 |
|
|
2018
Q1 | $10M | Buy |
94,013
+69,839
| +289% | +$7.53M | 0.24% | 96 |
|
|
2017
Q4 | $2.65M | Buy |
+24,174
| New | +$2.63M | 0.06% | 274 |
|
Other funds holding CRL
AI
Great Lakes Advisors's CRL Position: Q2 2026 in Review
Great Lakes Advisors held its Charles River Laboratories (CRL) position steady in Q2 2026 at 2,026 shares worth $459K. The position accounts for ﹤0.01% of the portfolio, ranked #626.
Great Lakes Advisors first reported a position in CRL in Q4 2017 and has held it in 32 quarters since. The position peaked at $35.9M in Q3 2021. 565 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Great Lakes Advisors held 2,026 shares of Charles River Laboratories worth $459K as of Q2 2026.
- Great Lakes Advisors left its Charles River Laboratories share count unchanged in Q2 2026.
- Charles River Laboratories made up ﹤0.01% of Great Lakes Advisors's portfolio in Q2 2026, its #626 holding.
- Great Lakes Advisors first reported a position in Charles River Laboratories in Q4 2017 and has held it in 32 quarters since.
- Great Lakes Advisors's Charles River Laboratories position peaked at $35.9M in Q3 2021.
- 565 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Great Lakes Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.